Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron’s Ultra-Orphan Arcalyst Hits The Market With A Rare Price

This article was originally published in The Pink Sheet Daily

Executive Summary

$250,000 per year wholesale acquisition cost to treat rare genetic disorder, firm tells “The Pink Sheet” DAILY.

You may also be interested in...



Regeneron’s Arcalyst Gets Advisory Committee For Niche Gout Indication

FDA’s Arthritis Advisory Committee will consider the interleukin-1 blocker for prevention of gout flares during initiation of uric-acid lowering therapy. Analysts say Arcalyst could have an easier time than Novartis’ Ilaris, which the panel felt had serious infection safety issues.

Novartis Ilaris Approved For Rare Autoinflammatory Disorder; Filings For More Common Diseases Planned

Development portfolio for interleukin-1ß blocker is sign of success for Novartis proof of concept R&D development model.

Novartis Ilaris Approved For Rare Autoinflammatory Disorder; Filings For More Common Diseases Planned

Development portfolio for interleukin-1ß blocker is sign of success for Novartis proof of concept R&D development model.

Related Content

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel